[
  {
    "ts": null,
    "headline": "Top 15 High-Growth Dividend Stocks For November 2025",
    "summary": "Explore November 2025's top 15 high-growth dividend stocksâ1.39% yield, 19.88% 5-year growth.",
    "url": "https://finnhub.io/api/news?id=92d6c4f895175fa22d42653bef00c357970fe7336e8cb82e8992caf3851d2a63",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762038050,
      "headline": "Top 15 High-Growth Dividend Stocks For November 2025",
      "id": 137290967,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165465384/image_2165465384.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore November 2025's top 15 high-growth dividend stocksâ1.39% yield, 19.88% 5-year growth.",
      "url": "https://finnhub.io/api/news?id=92d6c4f895175fa22d42653bef00c357970fe7336e8cb82e8992caf3851d2a63"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer",
    "summary": "We recently published 10 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) continues to be one of Cramer’s top pharmaceutical stocks. He has consistently discussed the firm in 2025 and praised it on several fronts. These include Eli Lilly […]",
    "url": "https://finnhub.io/api/news?id=34e0dfd1ffca5a1b7cfa7957a32403dfef2866f5af83a883af193e5dba644823",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762025371,
      "headline": "Eli Lilly (LLY) Would Be Up More If The Market Weren’t That Bad, Says Jim Cramer",
      "id": 137294500,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company (NYSE:LLY) continues to be one of Cramer’s top pharmaceutical stocks. He has consistently discussed the firm in 2025 and praised it on several fronts. These include Eli Lilly […]",
      "url": "https://finnhub.io/api/news?id=34e0dfd1ffca5a1b7cfa7957a32403dfef2866f5af83a883af193e5dba644823"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points",
    "summary": "Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points.",
    "url": "https://finnhub.io/api/news?id=e220b223ff8fef26f617374d0c6470e878da8ce855b71b794ab5c1040cd9421c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761998423,
      "headline": "S&P 500 Giants JPMorgan, Eli Lilly Lead Five Stocks Near Buy Points",
      "id": 137294486,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Three S&P 500 components, including JPMorgan Chase and Eli Lilly, are among five stocks near buy points.",
      "url": "https://finnhub.io/api/news?id=e220b223ff8fef26f617374d0c6470e878da8ce855b71b794ab5c1040cd9421c"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia's dizzying week of dealmaking",
    "summary": "The AI chip darling already has the most cutting-edge products and the best customers. The next thing to do is to find more of them.",
    "url": "https://finnhub.io/api/news?id=9973b7dc0c410d339114aafc45bfdf38157be00e618838aa0b85567b1a69ba50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761994836,
      "headline": "Nvidia's dizzying week of dealmaking",
      "id": 137294502,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The AI chip darling already has the most cutting-edge products and the best customers. The next thing to do is to find more of them.",
      "url": "https://finnhub.io/api/news?id=9973b7dc0c410d339114aafc45bfdf38157be00e618838aa0b85567b1a69ba50"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Profit Growth Surges 120%, Reinforcing Bullish Narrative Despite Premium Valuation",
    "summary": "Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a year ago. Looking ahead, earnings are forecast to grow at 19.3% per year, outpacing the broader US market's 15.9% estimate. Despite a lofty Price-to-Earnings ratio of 42 times, which sits well above industry norms, the current share price of $862.86 still trails a discounted cash flow fair value...",
    "url": "https://finnhub.io/api/news?id=d810f8eea9d770dbdef2b4bfab64bf18b4003ab87ec73b5fc9b372cac4693a53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761974337,
      "headline": "Eli Lilly (LLY) Profit Growth Surges 120%, Reinforcing Bullish Narrative Despite Premium Valuation",
      "id": 137294503,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a year ago. Looking ahead, earnings are forecast to grow at 19.3% per year, outpacing the broader US market's 15.9% estimate. Despite a lofty Price-to-Earnings ratio of 42 times, which sits well above industry norms, the current share price of $862.86 still trails a discounted cash flow fair value...",
      "url": "https://finnhub.io/api/news?id=d810f8eea9d770dbdef2b4bfab64bf18b4003ab87ec73b5fc9b372cac4693a53"
    }
  }
]